Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27%
May 11
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 12, 2025
DataAggregated Company Financials
Companies563
- 7D-8.7%
- 3M-11.8%
- 1Y-15.3%
- YTD-10.2%
Over the last 7 days, the Biotech industry has dropped 8.7%, driven by AbbVie declining 7.0%. Meanwhile, Neurocrine Biosciences actually outperformed within the industry, gaining 5.5% in the last week. Overall the industry is down 15% in 12 months. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 12 May 2025 | US$861.1b | US$154.9b | -US$24,538,327,634.73 | 16.7x | -35.1x | 5.6x |
| Wed, 09 Apr 2025 | US$728.1b | US$118.6b | -US$36,894,652,377.23 | 19.3x | -19.7x | 6.1x |
| Fri, 07 Mar 2025 | US$848.3b | US$119.0b | -US$37,227,382,606.31 | 16.9x | -22.8x | 7.1x |
| Sun, 02 Feb 2025 | US$1.0t | US$149.5b | -US$26,306,804,829.57 | 17.2x | -38.1x | 6.7x |
| Tue, 31 Dec 2024 | US$977.8b | US$149.6b | -US$26,368,249,096.05 | 16.9x | -37.1x | 6.5x |
| Thu, 28 Nov 2024 | US$1.0t | US$150.0b | -US$26,605,248,182.60 | 16.6x | -38.7x | 6.9x |
| Sat, 26 Oct 2024 | US$886.8b | US$113.1b | -US$36,035,376,152.30 | 20.6x | -24.6x | 7.8x |
| Mon, 23 Sep 2024 | US$920.0b | US$113.2b | -US$35,983,947,157.41 | 21.9x | -25.6x | 8.1x |
| Wed, 21 Aug 2024 | US$905.2b | US$113.2b | -US$35,832,221,284.65 | 22.9x | -25.3x | 8x |
| Fri, 19 Jul 2024 | US$1.2t | US$164.5b | -US$28,050,002,699.28 | 29x | -43.2x | 7.4x |
| Sun, 16 Jun 2024 | US$1.2t | US$164.4b | -US$28,071,754,707.37 | 27.3x | -41.2x | 7x |
| Tue, 14 May 2024 | US$1.1t | US$164.7b | -US$26,999,224,352.94 | 23.2x | -41.7x | 6.8x |
| Thu, 11 Apr 2024 | US$1.1t | US$164.3b | -US$23,371,324,513.62 | 21.4x | -48.7x | 6.9x |
| Sat, 09 Mar 2024 | US$1.2t | US$167.3b | -US$22,121,973,439.03 | 19x | -54x | 7.1x |
| Mon, 05 Feb 2024 | US$1.4t | US$203.9b | -US$24,425,425,728.00 | 19.2x | -58.9x | 7.1x |
| Wed, 03 Jan 2024 | US$1.4t | US$204.8b | -US$22,201,360,571.00 | 21x | -63.9x | 6.9x |
| Fri, 01 Dec 2023 | US$1.2t | US$204.7b | -US$22,039,871,274.00 | 18.5x | -56x | 6x |
| Sun, 29 Oct 2023 | US$1.2t | US$206.6b | -US$15,166,070,486.00 | 16.3x | -77.7x | 5.7x |
| Tue, 26 Sep 2023 | US$1.3t | US$207.4b | -US$12,899,236,949.00 | 17x | -97.7x | 6.1x |
| Thu, 24 Aug 2023 | US$1.3t | US$207.6b | -US$12,449,828,498.00 | 17.5x | -103.1x | 6.2x |
| Sat, 22 Jul 2023 | US$1.2t | US$186.5b | -US$16,009,709,300.00 | 12.8x | -72x | 6.2x |
| Mon, 19 Jun 2023 | US$1.2t | US$186.3b | -US$16,034,836,469.00 | 12.1x | -72.3x | 6.2x |
| Wed, 17 May 2023 | US$1.2t | US$191.6b | -US$12,334,188,018.00 | 13.3x | -93.3x | 6x |
| Fri, 14 Apr 2023 | US$1.2t | US$198.6b | -US$3,203,316,182.00 | 14.2x | -369.1x | 6x |
| Sun, 12 Mar 2023 | US$1.1t | US$199.3b | -US$4,751,094,936.00 | 14.9x | -230.3x | 5.5x |
| Tue, 07 Feb 2023 | US$1.2t | US$202.1b | US$1.8b | 16.4x | 644.8x | 5.7x |
| Thu, 05 Jan 2023 | US$1.2t | US$203.3b | US$1.6b | 14.4x | 711.3x | 5.7x |
| Sat, 03 Dec 2022 | US$1.2t | US$202.6b | US$1.4b | 15.1x | 843.3x | 5.8x |
| Mon, 31 Oct 2022 | US$1.1t | US$205.9b | US$7.4b | 14.3x | 148.7x | 5.3x |
| Wed, 28 Sep 2022 | US$1.0t | US$205.7b | US$5.5b | 13.9x | 186.2x | 4.9x |
| Fri, 26 Aug 2022 | US$1.1t | US$206.2b | US$7.2b | 15.9x | 148x | 5.2x |
| Sun, 24 Jul 2022 | US$1.1t | US$211.4b | US$11.3b | 15.8x | 93.8x | 5x |
| Tue, 21 Jun 2022 | US$952.1b | US$212.4b | US$11.0b | 14.8x | 86.4x | 4.5x |
| Thu, 19 May 2022 | US$1.0t | US$212.1b | US$10.7b | 14.6x | 93.9x | 4.7x |
Price to Earnings Ratio
93.9x
Current Industry PE
- Investors are pessimistic on the American Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.3x is higher than the industry's current PS ratio of 5.6x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 0.30% | |
| Healthcare | -4.12% | |
| Biotech | -8.72% | |
| Biotech | -8.72% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | US$115.71 | 5.4% +US$589.8m | -15.0% | PE37.4x | |
| HALO Halozyme Therapeutics | US$65.87 | 7.6% +US$557.6m | 52.7% | PE16.7x | |
| ALVO Alvotech | US$9.68 | 17.8% +US$440.6m | -27.6% | PE30.3x | |
| ACAD ACADIA Pharmaceuticals | US$17.44 | 17.0% +US$432.0m | 14.4% | PE12.8x | |
| BCRX BioCryst Pharmaceuticals | US$9.97 | 11.6% +US$218.0m | 87.4% | PS4.1x |
